Table. 5.

Comparison of clinical characteristics, outcomes, and management with other large cohort studies of COVID-19 in KTXs

Variable ASTREGO
(n=87)
South Asia
(n=250)
West Asia
(n=130)
Europe
(n=279)
North America
(n=54)
South America (n=491)
Representative nation East and Southeast Asia India [5] Saudi Arabia [6] France [7] New York [8] Brazil [9]
Age (yr) 43 (21–80) 43 (35–51) 48.7±14.4 Outpatient, 55.6 (48–61.1); inpatient, 61.6 (50.8–69.0) 57 (29–83) 53 (43–60)
Living donor kidney transplant 79 90 80 NA 69 33
COVID-19 within the first year of transplantation 12 20 16 14.4 Outpatient, 18; inpatient, 13 13.8
Hypertension 53 84 79 80.6 93 68
Diabetes 22 32 45 37.2 30 32
Cardiac disease 13 12 17 31.2 35 12
Most common immunosuppressiona)
Calcineurin inhibitor 100 94.4 96 83.1 100 Tacrolimus
Prednisolone 91 100 98 72.8 31.5 Prednisolone
Anti-metabolite 71 100 93 79.8 96.3 Mycophenolate
mTOR inhibitor and others 3 5.6 5 11.9 3.7 46
Asymptomatic case 15 6 1 0 0 3
Most common symptom Cough, 66; fever, 63; anorexia, 30 Fever, 88; cough, 72; sputum, 52 Fatigue, 62; fever, 60; cough, 58 Fever, 80; cough, 63.6; diarrhea, 43.5 Fever, 74; cough, 59; dyspnea, 52 Cough, 62; fever, 60; dyspnea, 51
Radiological abnormality 50.7 51 33.1 87 NA 97.3
Hospital admission 90.8 80 55 87 72 69
ICU admission 10.3 21 21 36 33 61
Ventilation 14.5 12 42 30 28 32
AKI 28.7 48.4 27 43.6 51 47
Shock 8 NA 11 11 NA 29
Secondary infection 5 20 29 23.5 48 36
Mortality 23 12 11 23 13 28
Reduction or discontinuation of immunosuppression
Calcineurin inhibitor 26 34 35 29 33 1
Antimetabolite (azathioprine/mycophenolic acid) 47 98 88 71 72 12
Adjustment in corticosteroids 68 40 77 NA 9 2
Azithromycin 16 80 31 25 22 45
Hydroxychloroquine 19 64 11 25 62 12
Antivirals 50 36 20 8 4 0
Antibiotics 45 NA 31 63 39 14
Immunotherapy 0 14 5 5 4 0
Convalescent plasma 0 6 5 0 2 0

Values are presented as median (interquartile range), mean±standard deviation, or percentages.

COVID-19, coronavirus disease 2019; KTX, kidney transplant recipients; ASTREGO, ASTREG research group; NA, data not available; mTOR, mammalian target of rapamycin; ICU, intensive care unit; AKI, acute kidney injury.

a)Data presented from the French study include only those who are hospitalized.

Korean J Transplant 2021;35:218~229 https://doi.org/10.4285/kjt.21.0024
© Clin Transplant Res